恒生医药ETF: 华夏恒生生物科技交易型开放式指数证券投资基金(QDII)2025年中期报告

Fund Overview - The fund is named "Huaxia Hang Seng Biotechnology Exchange-Traded Fund (QDII)" and aims to closely track the Hang Seng Biotechnology Index, which reflects the performance of the largest 50 biotechnology companies listed in Hong Kong [1][12] - The fund was established on September 29, 2021, and is managed by Huaxia Fund Management Co., Ltd. with China Agricultural Bank as the custodian [1][4] - As of June 30, 2025, the total fund shares amounted to 5,933,266,022 [1][19] Financial Performance - The fund reported a profit of approximately 1.79 billion RMB for the first half of 2025 [2] - The net asset value per share at the end of the reporting period was 0.7256 RMB, with a net value growth rate of 51.45% [14][19] - The fund's cumulative net value growth rate since inception is -27.44% [6][14] Investment Strategy - The fund employs a combination of strategies including full replication, alternative strategies, and derivatives to minimize tracking error and closely follow the benchmark index [1][12] - The fund's performance benchmark is the return of the Hang Seng Biotechnology Index, adjusted for valuation exchange rates [1][12] Market Context - The Hong Kong stock market showed strong performance in the first half of 2025, with significant inflows from southbound funds, particularly in sectors like AI technology, new consumption, and innovative pharmaceuticals [13][15] - The fund's investment operations were conducted with a focus on maintaining liquidity and stability, responding to investor subscriptions, redemptions, and adjustments in constituent stocks [13][14] Management and Compliance - Huaxia Fund Management Co., Ltd. is recognized as one of the largest ETF asset management companies in China, with a comprehensive product line covering various indices [5][8] - The fund management strictly adheres to relevant laws and regulations, ensuring fair treatment of all fund holders and maintaining transparency in operations [10][18]